Skip to main content
A
AGMB
(NASDAQ)
AgomAb Therapeutics NV
$10.51-- (--)
Loading... - Market loading

AgomAb Therapeutics NV (AGMB) Income Statement

Revenue, expenses, profit margins, and earnings with annual and quarterly data.

AgomAb Therapeutics NV Income Statement Analysis

Revenue, earnings, and profit margins in millions EUR

Scroll to see more
AgomAb Therapeutics NV income statement - Annual data in millions EUR
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2019FY 2018
Period EndingDec 2025Dec 2024Dec 2023Dec 2022Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.000.000.000.000.000.00
Cost of Revenue0.000.000.000.002.890.39
Gross Profit0.000.000.000.00-2.89-0.39
Operating Expenses
Research & Development48.8839.3126.3119.420.000.00
Selling, General & Administrative12.5710.136.004.510.200.00
Operating Expenses59.2848.0231.1922.630.200.00
Operating Income-59.28-48.02-31.19-22.63-3.09-0.39
Other Income/Expense
Interest Income1.611.270.250.070.030.00
Interest Expense0.06-0.070.03-0.05-0.040.00
Other Income/Expense-4.821.7618.9711.890.000.00
Income
Income Before Tax-62.55-46.26-12.01-10.81-3.10-0.39
Income Tax Expense0.000.00-0.62-2.66-0.050.00
Net Income-62.55-46.27-11.39-8.14-3.05-0.39
Net Income - Continuous Operations-62.55-46.27-11.39-8.140.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.00
EBITDA-62.27-47.71-11.88-22.610.000.00
EBIT-62.49-48.02-11.98-22.63-3.09-0.39
Depreciation & Amortization0.220.060.100.020.000.00
Earnings Per Share
Basic EPS-143.00-107.00--543.00--
Diluted EPS-143.00-107.00--543.00--
Basic Shares Outstanding0.540.5436.240.030.000.00
Diluted Shares Outstanding0.540.5436.240.030.000.00

These financial metrics are calculated using income statement data. Learn how each metric works and screen stocks by them.